Hedge Fund Stock Picks Based on Algo Trading: Returns up to 25.00% in 14 Days

Hedge Fund Stock Picks

This Hedge Fund Stocks Package is designed for investors and analysts who need predictions of the best-performing stocks according to I Know First’s stock market algorithm. It includes 20 stocks with bullish and bearish signals and indicates the best stocks to long and short based on artificial intelligence trading strategies:

  • Top 10 Hedge Fund stocks for the long position
  • Top 10 Hedge Fund stocks for the short position

hedgefunds
Package Name: Hedge Fund Stocks
Recommended Positions: Long
Forecast Length: 14 Days (12/08/2017 – 12/22/2017)
I Know First Average: 7.01%
Hedge Fund Stock Picks

In this 14 Days forecast for the Hedge Fund Stocks Package, there were many high performing trades and the algorithm correctly predicted 8 out 10 trades. The top-performing prediction in this forecast was TEVA, which registered a return of 25.00%. Other notable stocks were UAA and AAXN with a return of 16.72% and 8.67%. The package had an overall average return of 7.01%, providing investors with a premium of 5.25% over the S&P 500’s return of 1.76% during the same period.

Teva Pharmaceutical Industries Limited (TEVA) develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company’s Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The company’s Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited (TEVA) has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.